/
/
/

Alembic Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹2150 Cr₹1848 Cr₹1876 Cr₹1910 Cr₹1711 Cr₹1770 Cr₹1693 Cr₹1648 Cr₹1562 Cr₹1517 Cr₹1631 Cr₹1595 Cr₹1486 Cr₹1406 Cr₹1509 Cr₹1475 Cr₹1262 Cr₹1416 Cr₹1272 Cr₹1292 Cr₹1326 Cr₹1280 Cr₹1314 Cr₹1457 Cr₹1341 Cr₹1207 Cr₹1209 Cr₹1241 Cr₹949 Cr₹927 Cr₹1018 Cr₹1127 Cr₹863 Cr₹853 Cr₹840 Cr₹789 Cr₹648 Cr₹741 Cr₹777 Cr₹879 Cr₹737 Cr₹627 Cr₹916 Cr₹1004 Cr₹583 Cr₹503 Cr₹512 Cr₹547 Cr₹494 Cr₹464 Cr₹486 Cr₹486 Cr₹427 Cr₹378 Cr₹369 Cr₹407 Cr
₹15 Cr₹26 Cr₹16 Cr₹7 Cr₹7 Cr₹14 Cr₹10 Cr₹17 Cr₹2 Cr₹4 Cr₹3 Cr₹10 Cr₹12 Cr₹89 L₹44 L₹33 L₹1 Cr₹10 Cr₹15 Cr₹2 Cr₹4 Cr₹4 Cr₹3 Cr₹3 Cr₹32 L₹89 L₹41 L₹36 L₹3 Cr₹3 Cr₹4 Cr₹2 Cr₹10 L₹64 L₹33 L₹8 Cr₹17 L₹45 L₹35 L₹63 L₹60 L₹3 Cr₹3 Cr₹5 L₹3 L₹2 Cr₹31 L₹14 L₹18 L₹3 Cr₹20 L₹20 L₹2 L₹7 L₹3 Cr₹22 L
₹2165 Cr₹1873 Cr₹1892 Cr₹1917 Cr₹1717 Cr₹1784 Cr₹1702 Cr₹1665 Cr₹1564 Cr₹1521 Cr₹1633 Cr₹1605 Cr₹1498 Cr₹1407 Cr₹1509 Cr₹1475 Cr₹1263 Cr₹1426 Cr₹1287 Cr₹1295 Cr₹1330 Cr₹1284 Cr₹1317 Cr₹1460 Cr₹1342 Cr₹1208 Cr₹1210 Cr₹1241 Cr₹952 Cr₹930 Cr₹1022 Cr₹1129 Cr₹863 Cr₹854 Cr₹840 Cr₹797 Cr₹648 Cr₹742 Cr₹777 Cr₹880 Cr₹737 Cr₹630 Cr₹919 Cr₹1004 Cr₹583 Cr₹505 Cr₹512 Cr₹547 Cr₹494 Cr₹467 Cr₹486 Cr₹487 Cr₹427 Cr₹378 Cr₹373 Cr₹407 Cr
₹1916 Cr₹1708 Cr₹1663 Cr₹1671 Cr₹1503 Cr₹1567 Cr₹1503 Cr₹1479 Cr₹1394 Cr₹1326 Cr₹1434 Cr₹1454 Cr₹1354 Cr₹1268 Cr₹1327 Cr₹1310 Cr₹1315 Cr₹1379 Cr₹1086 Cr₹1090 Cr₹1145 Cr₹990 Cr₹996 Cr₹1057 Cr₹975 Cr₹923 Cr₹926 Cr₹931 Cr₹759 Cr₹779 Cr₹805 Cr₹853 Cr₹739 Cr₹712 Cr₹679 Cr₹636 Cr₹569 Cr₹628 Cr₹653 Cr₹722 Cr₹599 Cr₹508 Cr₹554 Cr₹642 Cr₹491 Cr₹416 Cr₹422 Cr₹450 Cr₹409 Cr₹384 Cr₹394 Cr₹404 Cr₹365 Cr₹321 Cr₹309 Cr₹351 Cr
₹347 Cr₹253 Cr₹309 Cr₹323 Cr₹288 Cr₹286 Cr₹270 Cr₹256 Cr₹239 Cr₹264 Cr₹269 Cr₹218 Cr₹210 Cr₹213 Cr₹249 Cr₹233 Cr₹16 Cr₹170 Cr₹257 Cr₹259 Cr₹238 Cr₹346 Cr₹368 Cr₹447 Cr₹408 Cr₹328 Cr₹325 Cr₹346 Cr₹228 Cr₹181 Cr₹246 Cr₹305 Cr₹151 Cr₹174 Cr₹188 Cr₹187 Cr₹102 Cr₹136 Cr₹146 Cr₹178 Cr₹158 Cr₹146 Cr₹387 Cr₹376 Cr₹104 Cr₹100 Cr₹102 Cr₹108 Cr₹96 Cr₹94 Cr₹102 Cr₹93 Cr₹72 Cr₹66 Cr₹73 Cr₹65 Cr
₹28 Cr₹23 Cr₹23 Cr₹24 Cr₹24 Cr₹25 Cr₹22 Cr₹19 Cr₹13 Cr₹11 Cr₹15 Cr₹16 Cr₹14 Cr₹14 Cr₹15 Cr₹12 Cr₹9 Cr₹7 Cr₹4 Cr₹5 Cr₹2 Cr₹3 Cr₹2 Cr₹4 Cr₹7 Cr₹8 Cr₹7 Cr₹7 Cr₹5 Cr₹5 Cr₹6 Cr₹6 Cr₹2 Cr₹1 Cr₹82 L₹35 L₹89 L₹2 Cr₹95 L₹1 Cr₹1 Cr₹2 Cr₹1 Cr₹73 L₹62 L₹36 L₹0₹1 Cr₹56 L₹2 Cr₹3 Cr₹3 Cr₹1 Cr₹2 Cr₹4 Cr₹3 Cr
₹221 Cr₹118 Cr₹163 Cr₹222 Cr₹191 Cr₹193 Cr₹177 Cr₹180 Cr₹157 Cr₹183 Cr₹185 Cr₹135 Cr₹130 Cr₹125 Cr₹168 Cr₹153 Cr-₹60 Cr₹41 Cr₹197 Cr₹200 Cr₹183 Cr₹292 Cr₹318 Cr₹398 Cr₹360 Cr₹266 Cr₹276 Cr₹303 Cr₹155 Cr₹146 Cr₹211 Cr₹270 Cr₹122 Cr₹141 Cr₹161 Cr₹161 Cr₹79 Cr₹112 Cr₹124 Cr₹157 Cr₹137 Cr₹120 Cr₹364 Cr₹362 Cr₹91 Cr₹88 Cr₹90 Cr₹96 Cr₹85 Cr₹81 Cr₹89 Cr₹80 Cr₹61 Cr₹55 Cr₹60 Cr₹53 Cr
₹172 Cr₹200 Cr₹134 Cr₹182 Cr₹154 Cr₹157 Cr₹137 Cr₹152 Cr₹134 Cr₹179 Cr₹181 Cr₹137 Cr₹121 Cr₹161 Cr₹136 Cr₹135 Cr-₹59 Cr₹34 Cr₹168 Cr₹161 Cr₹148 Cr₹237 Cr₹259 Cr₹325 Cr₹293 Cr₹204 Cr₹228 Cr₹250 Cr₹119 Cr₹131 Cr₹171 Cr₹200 Cr₹90 Cr₹102 Cr₹131 Cr₹124 Cr₹63 Cr₹95 Cr₹84 Cr₹124 Cr₹104 Cr₹91 Cr₹269 Cr₹288 Cr₹72 Cr₹70 Cr₹71 Cr₹77 Cr₹65 Cr₹61 Cr₹66 Cr₹62 Cr₹47 Cr₹44 Cr₹48 Cr₹42 Cr

Share Price Live Stats

Open (₹)805.00
Volume (₹)43,772.00
High (₹)811.75
Upper Circuit964.35
Low (₹)798.00
Lower Circuit642.95
Prev Close803.65
52W High (₹)998.00
Price799.50
52W Low (₹)635.80

Share Market Cap & Key Ratios Overview

M.Cap (₹)15805.60 Cr
Div. Yield (%)1.49
PE Ratio22.79
Debt to Equity0.24
Price to Book2.29
Book Value288.72
EPS (TTM)35.28
Face Value2.00
ROE (%)12.35

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
APLLTDNSE
LTP
1W Low
1W High
Market cap (₹)
1904.5-15.5 (-0.81%)
1902
1984.80
4,56,833Cr
9183-56 (-0.61%)
9087
9467
2,45,426Cr
4898.5-151.5 (-3.00%)
4886.50
5066
1,87,320Cr
1133.3-57.7 (-4.84%)
1125.10
1187
1,13,217Cr
1390.6-32.9 (-2.31%)
1376.70
1426.10
1,12,212Cr
1852.2-86.3 (-4.45%)
1811.70
1949
1,01,155Cr
2124-47.5 (-2.19%)
2118.10
2192
97,626Cr
2350-32.9 (-1.38%)
2341.20
2419.20
96,859Cr
1163.6-14.4 (-1.22%)
1154.40
1179.90
96,406Cr
1653+7.7 (0.47%)
1622.60
1717
93,614Cr
799.5-13.95 (-1.71%)
798
859
15,806Cr

Key Highlights of Alembic Pharmaceuticals Ltd’s P&L

In 2026-03-31, Alembic Pharmaceuticals Ltd reported total revenue of ₹7399.78Cr, compared with ₹6719.95Cr in 2025-03-31, reflecting Alembic Pharmaceuticals Ltd turnover.

Depreciation was ₹318.55Cr and finance costs were ₹93.63Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹693.95Cr in 2026-03-31 as compared to ₹707.18Cr in 2025-03-31.

Net Profit (PAT) was ₹674.77Cr in 2026-03-31 compared with ₹583.42Cr in 2025-03-31.

Earnings per share (EPS) were ₹34.33 in 2026-03-31, compared with ₹29.68 in 2025-03-31.